Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIRASOL: Mirvetuximab Soravtansine vs Chemotherapy in Platinum-Resistant Ovarian Cancer
NCT04209855Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Dec 2019
- Primary completion
- Mar 2023
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 21
01
Overview
A Phase 3 trial of mirvetuximab soravtansine in High-Grade Serous Ovarian Cancer (HGSOC), primary peritoneal cancer (PPC), fallopian tube cancer (PFTC), sponsored by AbbVie Inc.. Started Dec 2019; status: completed.
02
Drugs
mirvetuximab soravtansine
03
Conditions
High-Grade Serous Ovarian Cancer (HGSOC)primary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT04209855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04209855.